JM Bekshin¹, M Rysuly², AT Abishev³, GK Akhmetova⁴ and AS Sadvakas⁵*

¹Head of the Department of Sanitary and Epidemiological Control for the City of Almaty, Kazakhstan

*Corresponding Author: AS Sadvakas, Assistant of the Department of Clinical Laboratory Diagnostics, Asfendiyarov Kazakh National Medical University, Kazakhstan.

Received: February 09, 2023; Published: February 22, 2023

Abstract

Post-vaccination measurement of the level of antibodies neutralizing the SARS-CoV-2 virus (NA) in blood serum is a marker for monitoring the effectiveness of immunity formation [1,2]. In 4 groups of 462 patients, a comparative study of the neutralizing effectiveness of antibodies was carried out with single and double administration of CoronaVac brand vaccines (SynoVac), VeroCell (Sinofarm), Sputnik-V (GamCovidVac) and domestically produced QazVac (QazCovid-in). Of the 462 vaccinated subjects examined for NA, 46 recovered from COVID-19 and 416 were not infected with the SARS CoV-2 virus. The latter were included in the present study. In 34 (8.2%) patients, threshold values of NA were not found in the blood serum after vaccination. The Chinese-made vaccines Vero-Cell and the Kazakhstani manufacturer QazCovid (Research Institute for Biological Safety of the Ministry of Education and Science of the Republic of Kazakhstan) had practically the same indicators of post-vaccination immunogenicity.

Keywords: Vaccines; CoronaVac (SynoVac); VeroCell (Sinofarm); Sputnik-V (GamCovidVac); QazVac (QazCovid-in); SARS-CoV-2 IgG Neutralizing Antibodies; Quantitatively; Coronavirus-19

References

1. Evaluation of COVID-19 vaccine effectiveness. WHO, Interim Guidance. 17 March (2021): 60.
2. Plotkin SA and Gilbert PB. “Nomenclature for immune correlates of protection after vaccination”. Clinical Infectious Diseases 54.11 (2012): 1615-1617.
3. Fei Xiang., et al. “Antibody Detection and Dynamic Characteristics in Patients with COVID-19”. Clinical Infectious Diseases, ciaa461.
4. Takahashi T and Iwasaki A. “Sex differences in immune responses”. Science 6527 (2021): 347-348.
5. Thailand Food and Drug Administration. Summary of Product Characteristic CoronaVac (2021).
6. Zhang Y., et al. “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial”. Lancet Infectious Diseases 2 (2021): 181-192.
7. Voysey M., et al. “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. Lancet 10269 (2021): 99-111.
8. Thompson MG., et al. “Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. The New England Journal of Medicine 4 (2021): 320-329.
9. Al Kaabi N., et al. “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial”. JAMA 1 (2021): 32635-32645.
10. Yan ZP., et al. “COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials”. Pharmaceuticals (Basel)5 (2021): 406.
11. Madhi SA., et al. “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”. The New England Journal of Medicine 20 (2021): 1885-1898.
12. Pan H., et al. “Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial”. medRxiv (2021).
13. Sterlin D., et al. “IgA dominates the early neutralizing antibody response to SARS-CoV-2”. Science Translational Medicine 577 (2021).
14. Madhi SA., et al. “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”. The New England Journal of Medicine (2021).
15. Rossman H., et al. “COVID-19 dynamics after a national immunization program in Israel”. Nature Medicine (2021).
16. Dejnirattisai W., et al. “Antibody evasion by the P.1 strain of SARS-CoV-2”. Cell (2021).
17. Yuan M., et al. “Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies”. Biochemical and Biophysical Research Communications 538 (2021): 192-203.
18. Greaney AJ., et al. “The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD”. bioRxiv (2021).
19. Abu-Raddad LJ., et al. “Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses”. Journal of Travel Medicine (2021).
20. Earle KA., et al. “Evidence for antibody as a protective correlate for COVID-19 vaccines”. medRxiv (2021): 03.17.20200246.
21. Khoury DS., et al. “Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection”. Nature Medicine (2021).
22. Craig Fenwickhttps., et al. “Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies”. Journal of Virology3 (2021): e01828-20.
23. Zhao J., et al. “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”. Clinical Infectious Diseases (2019).

Citation

Citation: AS Sadvakas., et al. “Post-vaccination Comparative Studies of the Dynamics of Antibodies Neutralizing the SARS-CoV-2 Virus During Vaccination with Various Vaccines in Kazakhstan". Acta Scientific Gastrointestinal Disorders 6.3 (2023): 21-30.

Copyright

Copyright: © 2022 AS Sadvakas., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.